Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients withMetastatic Melanoma

Hadassah Medical Center, Hebrew University, Kiryat Hadassah, 91120 Jerusalem, Israel 2 Chaim Sheba Medical Center, Tel Hashomer, 52621 Ramat Gan, Israel 3 Sackler Faculty of Medicine, Tel Aviv Medical Center, 69978 Tel Aviv, Israel 4 Rambam Health Care Campus, 31096 Haifa, Israel 5 Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA 6 Pain erapeutics, Inc., Austin, TX 78731, USA Davis Medical Center, University of California, Sacramento, CA 95817, USA

[1]  K. Flaherty,et al.  BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[3]  Myles G Cockburn,et al.  Increasing burden of melanoma in the United States. , 2009, The Journal of investigative dermatology.

[4]  A. Casadevall,et al.  Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice , 2008, Cancer biology & therapy.

[5]  Vineet Rakesh,et al.  Computational model predicts effective delivery of 188-Re-labeled melanin-binding antibody to metastatic melanoma tumors with wide range of melanin concentrations , 2007, Melanoma research.

[6]  Michael G Stabin,et al.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  D. Goldenberg,et al.  Perspectives on cancer therapy with radiolabeled monoclonal antibodies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  A. Casadevall,et al.  Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[9]  B. Wessels,et al.  Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  M. Brechbiel,et al.  Antibody-targeted radiation cancer therapy , 2004, Nature Reviews Drug Discovery.

[11]  Suzie Chen,et al.  Progressive appearance of pigmentation in amelanotic melanoma lesions. , 2002, Pigment cell research.

[12]  A. Halpern,et al.  Detection of clinically amelanotic malignant melanoma and assessment of its margins by in vivo confocal scanning laser microscopy. , 2001, Archives of dermatology.

[13]  A. Casadevall,et al.  Synthesis of Polymerized Melanin by Cryptococcus neoformans in Infected Rodents , 2000, Infection and Immunity.

[14]  B. Levin,et al.  Quantitation of human tumor-reactive monoclonal antibody 16.88 in the circulation and localization of 16.88 in colorectal metastatic tumor tissue using murine antiidiotypic antibodies. , 1992, Cancer research.

[15]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[16]  S. Larson,et al.  Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: preliminary experience. , 1985, Radiology.